Moreover, RBBP8 deficiency has been associated with increase the susceptibility of breast and ovarian cancer to poly ADP ribose polymerase (PARP) inhibitors in a manner similar to BRCA1 mutations (Lin et al. 2014; Wang et al. 2016) which suggests a possible benefit of difficult to manage MIBC from this approach. Here, RBBP8 is linked to ovarian carcinoma.